Aequus Pharmaceuticals (CVE:AQS) Stock Price Up 100%

Aequus Pharmaceuticals Inc. (CVE:AQS)’s share price traded up 100% during trading on Wednesday . The stock traded as high as C$0.04 and last traded at C$0.04. 420,800 shares were traded during trading, an increase of 103% from the average session volume of 206,982 shares. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Stock Performance

The company’s 50-day simple moving average is C$0.02 and its 200 day simple moving average is C$0.02. The company has a current ratio of 0.09, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The stock has a market cap of C$5.31 million, a P/E ratio of -1.50 and a beta of 0.17.

Aequus Pharmaceuticals (CVE:AQS) last issued its quarterly earnings results on Monday, April 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The firm had revenue of C$0.05 million for the quarter. As a group, sell-side analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current fiscal year.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.